The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 93%. Our forward projection puts the odds of a 10% gain over the next month near 16%.
BiomX Inc
PHGE · NYSE AMERICAN · USD · Market cap $2M · 20 employees
BiomX Inc., a holding company, focuses on defense, security, and critical infrastructure technologies.
FAIL · Does not pass the screenAt the last full screen
2025-12-31
Screened 2025-12-31 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its markup label.
BiomX Inc holds its Markup at $0.20. Elevated stress, defensive posture warranted, held for 7 days.
| Phase | Markup |
| Quantitative state | Elevated stress, defensive posture warranted, held for 7 days |
| Price at the screen | $0.20 |
| Valuation | N/A trailing · -0.03 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.31 |
Five Screens, Shown in Full
Does not pass. Business activity: weapons
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Its core business involves an activity the values screen does not clear. | Fail |
| Debt load | 24.83% | Below 33% | Interest-bearing debt is just 24.8% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 75.39% | Below 49% | Money owed to the company is 75.4% of assets, above the 49% limit. | Fail |
| Revenue purity | Excluded | Below 5% | of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Business, in Plain Words| Forward P/E | 0.0x |
| EPS, trailing | -23.30 |
| EPS, forward | -6.01 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -403.8%not currently earning a positive return on equity |
| FCF yield | -695.05% |
| Current ratio | 1.24adequate liquidity, worth monitoring |
| Beta | 1.31moves a little more than the market |
| Short interest, float | 0.08% |
| 52-week range | 0.19 - 13.70 |
| Moat | NONE |
| Market cap | $2M |
| Employees | 20 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradePHGE trades on NYSE AMERICAN. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 62.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 93%. Our forward projection puts the odds of a 10% gain over the next month near 16%.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 93%. Our forward projection puts the odds of a 10% gain over the next month near 16%.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $0.68 | -6.4% | · | $936 | -6.4% |
| 2 months | $2.89 | -78.1% | · | $219 | -78.1% |
| 3 months | $6.37 | -90.1% | · | $99 | -90.1% |
| 6 months | $2.45 | -74.2% | · | $258 | -74.2% |
| 1 year | $8.55 | -92.6% | · | $74 | -92.6% |
| 2 years | $66.50 | -99.1% | · | $10 | -99.1% |
| 3 years | $67.45 | -99.1% | · | $9 | -99.1% |
| 5 years | $1,136.20 | -99.9% | · | $1 | -99.9% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever PHGE does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.